Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: Thirty-five patients were enrolled, with a median age of 68 years. A total of 89 cycles were administered (median, 2 cycles). Major toxicities were Grade 3/4 neutropenia in 28 (80.0%) patients and Grade 3/4 thrombocytopenia in 18 (51.5%). An objective response rate (ORR) was 11 of 21 patients (52.4%), including a complete response in 1 (4.8%). The median overall survival (OS) was 13.1 months (1-year survival rate, 60%) and the median progression-free survival (PFS) was 5.0 months. Among 16 patients who had previously received MVAC, the ORR, the median PFS, the median OS and 1-year survival rate was 56.3%, 5.0 months, 12.6 months and 54%, respectively. CONCLUSIONS: GCD chemotherapy is active and well tolerated as a first- or second-line therapy for patients with advanced UC. Response rate, duration and survival did not differ between those with and without a history of MVAC treatment.
|
Authors | Hiroshi Tsuruta, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Mitsuru Saito, Takashi Obara, Kazuyuki Numakura, Shinya Maita, Shigeru Satoh, Norihiko Tsuchiya, Tomonori Habuchi |
Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 16
Issue 5
Pg. 533-8
(Oct 2011)
ISSN: 1437-7772 [Electronic] Japan |
PMID | 21431341
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Taxoids
- Deoxycytidine
- Docetaxel
- Vinblastine
- Doxorubicin
- Carboplatin
- Cisplatin
- Methotrexate
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(adverse effects, therapeutic use)
- Carcinoma
(drug therapy, pathology)
- Cisplatin
(therapeutic use)
- Deoxycytidine
(adverse effects, analogs & derivatives, therapeutic use)
- Disease-Free Survival
- Docetaxel
- Doxorubicin
(therapeutic use)
- Female
- Humans
- Male
- Methotrexate
(therapeutic use)
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Taxoids
(adverse effects, therapeutic use)
- Urologic Neoplasms
(drug therapy, pathology)
- Vinblastine
(therapeutic use)
- Gemcitabine
|